- Home
- GDTC
as 12-18-2024 2:37pm EST
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Founded: | 2018 | Country: | Singapore |
| Employees: | N/A | City: | N/A |
| Market Cap: | 33.4M | IPO Year: | 2023 |
| Target Price: | $5.00 | AVG Volume (30 days): | 24.7K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $5.50 | Next Earning Date: | 01-01-0001 |
| Revenue: | $330,254 | Revenue Growth: | -21.95% |
| Revenue Growth (this year): | 14.71% | Revenue Growth (next year): | -8.93% |
Latest CytoMed Therapeutics Limited News
GDTC Breaking Stock News: Dive into GDTC Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch
GlobeNewswire
a month ago
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Simply Wall St.
2 months ago
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
GlobeNewswire
2 months ago
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
TipRanks
2 months ago
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
GlobeNewswire
3 months ago
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
GlobeNewswire
3 months ago
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
GlobeNewswire
3 months ago
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
Compare GDTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GDTC CytoMed Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.